ANI Pharmaceuticals has again beat some analyst estimates, receiving praise at a transformative point for the company following its acquisition of Alimera Sciences earlier in autumn.
Notably, ANI managed to beat revenue estimates for the 10th straight quarter, per an 11 November H.C
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?